Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10382): 1079-1090, 2023 04 01.
Article
in En
| MEDLINE
| ID: mdl-36868261
Full text:
1
Database:
MEDLINE
Main subject:
Angioedemas, Hereditary
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Lancet
Year:
2023
Type:
Article